Lundbeck appoints Senior Vice President for Business Development and HR

Valby, 2013-12-03 08:00 CET (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) incorporates the responsibility for the company's departments for business development and HR and has appointed Jacob Tolstrup Senior Vice President for the joint area. Having served as Vice President for Lundbeck's business development until now, Jacob Tolstrup will now extend his responsibilities.

Since 1999, Jacob Tolstrup has held a number of different positions with Lundbeck, including as Vice President for Investor Relations and Communications and as Vice President for Finance and Administration at Lundbeck's large subsidiary in the US. Since March 2012, he has been Vice President for Business Development, and his responsibilities will now also extend to the company's HR department, and he will have a reporting staff of 70. Jacob Tolstrup will continue to report to Lundbeck CEO Ulf Wiinberg.

The appointment comes in connection with the resignation of Teddy Hebo Larsen, Lundbeck's Vice President for HR since 2009, who has resigned at his own request. Teddy Hebo Larsen, who turned 60 in March of this year, intends to change his working life after a long, busy and successful executive career. He wishes to spend more time with his family and on private projects, including a small Danish business in which he is a shareholder.

"Throughout the roughly five years that Teddy has served as our head of HR, he has made a tremendous contribution to developing Lundbeck's work culture and the HR function, and I owe him many thanks for his efforts. At the same time, I am happy to appoint Jacob Tolstrup as Senior Vice President for business development and HR and look forward to drawing even more on Jacob's skills, while at the same time ensuring continuity in the management of our HR department," said Ulf Wiinberg.

Teddy Hebo Larsen will step down at the end of the year.

 

About Jacob Tolstrup

Date of birth: 3 May 1972 (41). Education: Graduated MSc in Business Law from Aalborg University. MBA from Germany.

Career:

2013- : Senior Vice President, Business Development and HR, Lundbeck.

2012-2013: Vice President, Business Development, Lundbeck.

2010-2012: Vice President, Finance and Administration, Lundbeck US, Lundbeck. 

2010-2010: Vice President, Investor Relations and Communications, Lundbeck.

2007-2010: Divisional Director, Investor Relations and Communications, Lundbeck.

2006-2007: Director of Finance and of Investor Relations, North America, Lundbeck.

2001-2006: Various positions in Investor Relations, Lundbeck.

1999-2001: Financial Analyst and Financial Planner, Lundbeck.

1998-1999: Finance Department, Abbott Laboratories.

 

Personal life: Married to Mette, who is an upper secondary school teacher. They have three children. Leisure activities include running and football. 
 

Contacts

Mads Kronborg, Media Relations Manager                     Søren Mikkel Berg, Media Relations

Telephone (direct): +45 36 43 28 51                                Telephone (direct): +45 36 43 49 80

About Lundbeck

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in the entire value chain throughout research, development, production, marketing and sales of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy, Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck's pipeline consists of several mid- to late- stage development programs.
Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are based in Denmark. We have employees in 57 countries, and our products are registered in more than 100 countries. We have research centres in Denmark, China and the United States and production facilities in Italy, France, Mexico, China and Denmark. Lundbeck generated revenue of approximately DKK 15 billion in 2012. For additional information, we encourage you to visit our corporate site www.lundbeck.com

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.